Lexicon Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Lexicon Pharmaceuticals generated cash of -$161,897,000, which is less than the previous year. Cash used in financing activities reached the amount of $187,960,000 last year. Net change in cash is therefore -$23,880,000.
Cash Flow
| 2014 | -75.62M | -108.41M | 283.80M |
|---|---|---|---|
| 2015 | 184.77M | -117.02M | -2.03M |
| 2016 | -175.62M | 18.25M | 987K |
| 2017 | -185.39M | 50.52M | 149.93M |
| 2018 | -148.60M | 169.57M | -2.24M |
| 2019 | 113.80M | -155.85M | -2.22M |
| 2020 | -142.96M | 380.75M | -147.63M |
| 2021 | -87.01M | 2.11M | 22.70M |
| 2022 | -88.85M | -71.07M | 142.20M |
| 2023 | -161.89M | -49.94M | 187.96M |
LXRX Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 46.34M | 64.06M | 126.26M | 36.11M | 80.38M | 61.66M | 46.6M | 202.98M | 137.26M | 37.49M |
Operating activities | ||||||||||
Net income | -177.11M | -101.94M | -87.75M | -58.57M | 130.13M | -120.54M | -129.05M | -141.42M | -4.68M | -100.29M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 554K | 427K | 292K | 2.93M | 3.65M | 3.68M | 3.39M | 2.05M | 727K | 1.92M |
Stock-based compensation expense | 14.34M | 11.52M | 10.57M | 13.27M | 14.21M | 0 | 9.47M | 7.45M | 6.84M | 7.08M |
| Deferred income tax benefit | 14.34M | 11.52M | 10.57M | 13.27M | 14.21M | 0 | 9.47M | 7.45M | 6.84M | 7.08M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -982K | -14K | 381K | 53.22M | -50.60M | -1.09M | 166K | -4.08M | 124K | 457K |
Inventories | -381K | 0 | 0 | 345K | 437K | -2.73M | -1.94M | 6.22M | -5.78M | -128K |
Accounts payable | 6.45M | 76K | -14.15M | -20.96M | 20.09M | -18.85M | -7.17M | 27.65M | 6.20M | 1.26M |
Cash generated by operating activities | -161.89M | -88.85M | -87.01M | -142.96M | 113.80M | -148.60M | -185.39M | -175.62M | 184.77M | -75.62M |
Investing activities | ||||||||||
Purchases Of Investments | -223.34M | -133.94M | -34.26M | -58.55M | -322.38M | -119.98M | -267.87M | -425.67M | -326.44M | -221.95M |
Investments In Property Plant And Equipment | -470K | -1.32M | -1.22M | -87K | -70K | -95K | -228K | -231K | -910K | -80K |
Acquisitions Net | 0 | 69.75M | -3.33M | 11.01M | 155.78M | 0 | 0 | 0 | 335K | 0 |
Cash generated by investing activities | -49.94M | -71.07M | 2.11M | 380.75M | -155.85M | 169.57M | 50.52M | 18.25M | -117.02M | -108.41M |
Financing activities | ||||||||||
Common Stock Issued | 138.82M | 94.20M | 37.08M | 69.97M | 0 | 732K | 7.98M | 3.62M | 114K | 202.27M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | -824K | -864K | -2.67M | -1.02M | -941K | -972K | -1.67M | -621K | -357K | -887K |
Repayments of term debt | 49.96M | 48.86M | -11.7M | -216.58M | -1.28M | -14.53M | 143.62M | -2.01M | -1.85M | -1.71M |
Cash used in financing activities | 187.96M | 142.20M | 22.70M | -147.63M | -2.22M | -2.24M | 149.93M | 987K | -2.03M | 283.80M |
Net Change In Cash | -23.88M | -17.72M | -62.19M | 90.15M | -44.27M | 18.72M | 15.06M | -156.38M | 65.72M | 99.76M |
Cash at end of period | 22.46M | 46.34M | 64.06M | 126.26M | 36.11M | 80.38M | 61.66M | 46.6M | 202.98M | 137.26M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |